— Know what they know.
Not Investment Advice

HAE

Haemonetics Corporation
1W: -2.3% 1M: -3.5% 3M: -26.8% YTD: -26.8% 1Y: -10.3% 3Y: -23.6% 5Y: -50.9%
$58.58
-0.32 (-0.54%)
After Hours: $59.56 (+0.98, +1.67%)
NYSE · Healthcare · Medical - Instruments & Supplies · $2.7B · Alpha Radar Neutral · Power 51
Smart Money Score
Moderate 50
Insider+$0.1M
Congress
ETF Holdings
Key Statistics
Market Cap$2.7B
52W Range47.32-87.32
Volume405,185
Avg Volume835,901
Beta0.31
Dividend
Analyst Ratings
10 Buy 10 Hold 0 Sell
Consensus Buy
Company Info
CEOChristopher A. Simon
Employees3,657
SectorHealthcare
IndustryMedical - Instruments & Supplies
IPO Date1991-05-10
125 Summer Street
Boston, MA 02110
US
781 848 7100
About Haemonetics Corporation

Haemonetics Corporation, a healthcare company, provides medical products and solutions. It operates through three segments: Plasma, Blood Center, and Hospital. The company offers automated plasma collection devices, related disposables, and software, including NexSys PCS and PCS2 plasmapheresis equipment and related disposables and intravenous solutions, as well as integrated information technology platforms for plasma customers to manage their donors, operations, and supply chain; and NexLynk DMS donor management system. It also provides automated blood component and manual whole blood collection systems, such as MCS brand apheresis equipment to collect specific blood components from the donor; disposable whole blood collection and component storage sets; SafeTrace Tx blood bank information system; and BloodTrack blood management software, a suite of blood management and bedside transfusion solutions that combines software with hardware components, as well as an extension of the hospital's blood bank information system. In addition, the company offers hospital products comprising TEG, ClotPro, and HAS hemostasis analyzer systems that provide a comprehensive assessment of a patient's overall hemostasis; TEG Manager software, which connects various TEG analyzers throughout the hospital, providing clinicians remote access to active and historical test results that inform treatment decisions; and Cell Saver Elite +, an autologous blood recovery system for cardiovascular, orthopedic, trauma, transplant, vascular, obstetrical, and gynecological surgeries. It markets and sells its products through direct sales force, independent distributors, and sales representatives. Haemonetics Corporation was founded in 1971 and is headquartered in Boston, Massachusetts.

Recent Insider Trades

NameTypeSharesPriceDate
KROLL MARK W P-Purchase 1,400 $70.56 2025-11-10
Galvin Roy F-InKind 145 $50.01 2025-10-31
Miller Laurie A. F-InKind 238 $49.95 2025-09-17
Zane Ellen M A-Award 2,693 2025-07-24
Pomeroy Claire A-Award 2,693 2025-07-24

Sign in to InsiderStreet

You'll also get our free weekly newsletter with
smart money signals, market insights, and alpha ideas.
Unsubscribe anytime.

For informational purposes only. Not investment advice. Data sourced from SEC filings. Privacy Terms